Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years Joseph.

Slides:

Advertisements

Similar presentations

Changes in Risk Profile Over Time in the Population of a Pediatric Heart Transplant Program Olaf Reinhartz, MD, Katsuhide Maeda, MD, Bruce A. Reitz, MD,

Advertisements

Robert M. Kaplan, PhD, Qiankun Sun, PhD, Keith S

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

What Predicts Long-Term Survival After Heart Transplantation

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years Joseph.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

Collision Tumor of Esophagus: Report of Three Cases

Robert L. Smith, MD, Morley A. Herbert, PhD, Todd M

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Andrew J. Graham, MD, MS, Fiona M. Shrive,

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly Trevor Williams,

Meta-Analysis of Survival After Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Mesothelioma Emanuela Taioli, MD, PhD, Andrea S. Wolf,

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients Macarena R.

Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era

Michael L. Bailey, MBBS, Sven M. Richter, MD, Daniel V

Castigliano M. Bhamidipati, DO, MS, George J

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Loretta Erhunmwunsee, MD, Brian C

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer Servet Bölükbas,

Emanuela Taioli, MD, PhD, Andrea S

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Brendon M. Stiles, MD, Farooq Mirza, MD, Jeffrey L. Port, MD, Paul C

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Demographic, Psychosocial, and Behavioral Factors Associated With Survival After Heart Transplantation Steven A. Farmer, MD, PhD, Kathleen L. Grady,

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Surgical Resection of Rare Esophageal Cancers

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Who Do You Say You Are? The Annals of Thoracic Surgery

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Influence of Cigarette Smoking on Survival and Tumor Invasiveness in Clinical Stage IA Lung Adenocarcinoma Ryo Maeda, MD, Junji Yoshida, MD, Genichiro.

Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer Stephen A. Barnett, MBBS, Robert.

Use of Amiodarone After Major Lung Resection

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

The Prognostic Value of the Number of Negative Lymph Nodes in Esophageal Cancer Patients After Transthoracic Resection Po-Kuei Hsu, MD, Chien-Sheng Huang,

Robert R. McMillan, MD, MPH, Camelia S. Sima, MD, MS, Nicole H

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? Samuel Kim, MD, David A. Bull, MD, Linda Garland, MD,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Lung Function and ECMO After Lung Transplantation

Determinants of Left Ventricular Dysfunction After Repair of Chronic Asymptomatic Mitral Regurgitation Vincent Chan, MD, MPH, Marc Ruel, MD, MPH, Elsayed.

Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma Arianna Barbetta, MD, Francisco Schlottmann, MD, Tamar Nobel, MD, David B.

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Characteristics of Malignant Pleural Mesothelioma in Women

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki,

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Editorial Board, January 2010

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Robert M. Kaplan, PhD, Qiankun Sun, PhD, Keith S

Joseph S. Friedberg, MD, Melissa J

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Very Prolonged Stay in the Intensive Care Unit After Cardiac Operations: Early Results and Late Survival Shuli Silberman, MD, Daniel Bitran, MD, Daniel.

Neoadjuvant Chemoradiation Therapy Is Beneficial for Clinical Stage T2 N0 Esophageal Cancer Patients Due to Inaccurate Preoperative Staging Jennifer.

Relevance of Lymph Node Micrometastases in Radically Resected Endobronchial Carcinoid Tumors Tommaso Claudio Mineo, MD, Gianluca Guggino, MD, Davide.

Mert Saynak, MD, Jessica Hubbs, MS, Jiho Nam, MD, Lawrence B

The Risk and Outcomes of Reoperative Tricuspid Valve Surgery

Predictors of Pleural Implants in Patients With Thymic Tumors

Matthew J. Schuchert, MD, Brian L

Mark I. Block, MD The Annals of Thoracic Surgery

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

J. Alberto Lopez, MD The Annals of Thoracic Surgery

Bryan M. Burt, MD, Santiago Ocejo, MD, Carlos M

Presentation transcript:

Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years Joseph S. Friedberg, MD, Charles B. Simone, MD, Melissa J. Culligan, RN, MS, Andrew R. Barsky, BS, Abigail Doucette, MPH, Sally McNulty, RN, Stephen M. Hahn, MD, Evan Alley, MD, PhD, Daniel H. Sterman, MD, Eli Glatstein, MD, Keith A. Cengel, MD, PhD The Annals of Thoracic Surgery Volume 103, Issue 3, Pages 912-919 (March 2017) DOI: 10.1016/j.athoracsur.2016.08.071 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Survival analysis of entire 73-patient cohort, overall survival (OS [dark gray line]) and progression-free survival (PFS [light gray line]). The Annals of Thoracic Surgery 2017 103, 912-919DOI: (10.1016/j.athoracsur.2016.08.071) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Effect of lymph node metastases on (A) survival and (B) progression-free survival. Analysis of the effect of lymph node metastases was performed, with patients grouped as either node negative (N0 [dark gray lines]) or node positive (N1 or N2 [light gray lines]). Overall survival for patients with lymph node metastases was 7.3 ± 0.16 years and for patients without lymph node metastases, it was 1.9 ± 0.5 years. Progression-free survival for patients with lymph node metastases was 2.2 ± 1.1 years, and for patients without lymph node metastases, it was 0.8 ± 0.1 years. The Annals of Thoracic Surgery 2017 103, 912-919DOI: (10.1016/j.athoracsur.2016.08.071) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Effect of first treatment failure site on (A) overall survival and (B) progression-free survival. Analysis of patterns of initial treatment failure was performed, with patients grouped as having initial recurrence involving (1) locoregional sites (light gray lines) or (2) distant with or without locoregional sites (dark gray lines). Overall survival for patients with initial treatment failure at only locoregional sites was 2.7 ± 0.9 years; for distant failure with or without locoregional sites, it was 1.9 ± 0.9 years. Progression-free survival for patients having only locoregional recurrence was 1.0 ± 0.3 years, and for patients having distant recurrence with or without locoregional recurrence, it was 1.0 ± 0.2 years. The Annals of Thoracic Surgery 2017 103, 912-919DOI: (10.1016/j.athoracsur.2016.08.071) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions